| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Tumor Biology |
Departments of Physiological Chemistry [A. H. K.], Pathology [H. H., C. K.], Gynecology [A. G. J. v. d. Z.], Medical Oncology [E. G. E. d. V.], Medical Microbiology, Molecular Virology Section [T. D.], Faculty of Medical Sciences, Groningen University Institute for Drug Exploration, University of Groningen, 9713 AV Groningen, the Netherlands
This study investigates whether and to what extent cyclooxygenase type-2 (COX-2) and inducible nitric oxide-synthase (iNOS), both known to have an immunosuppressive effect, are expressed in human ovarian tumors. Because COX-2 and iNOS can be expressed by activated macrophages, the presence of tumor-associated macrophages and the expression of COX-2 and iNOS by these tumor-associated macrophages were determined. The results obtained may provide insight into the function of COX-2 and iNOS expression by tumors. The expression of COX-2 and iNOS in tumor cells and macrophages was assessed in 18 malignant, 15 borderline, and 14 benign human ovarian tumors by immunohistochemical staining of frozen tissue sections. The intra- and peritumoral macrophages were stained using an anti-CD68 monoclonal antibody. Most of the malignant tumors (15 of 18), 10 of 15 borderline, and 9 of 14 benign tumors showed COX-2 expression in the epithelial cells, a result which indicates that COX-2 expression is not exclusive to malignancy. In addition, COX-2 staining was more intense in the epithelial cells of benign and borderline tumors than in malignant tumors. Weak iNOS staining was observed in 5 of 18 malignant, 4 of 15 borderline, and 5 of 14 benign tumors. The number of tumor-associated macrophages varied widely between the different tumors. The highest number of tumor-associated macrophages (
20/0.125 mm2) was observed in malignant tumors, whereas low to moderate intra- and peritumoral macrophage infiltration (5–20/0.125 mm2) was observed in the borderline and benign tumors. COX-2-positive tumor-associated macrophages were found in 3 of 18 malignant tumors, 7 of 15 borderline tumors, and 1 of 14 benign tumors. The number of COX-2-positive tumor-associated macrophages ranged from 3 to 30% of the total macrophage population. Some malignant (4 of 18), borderline (5 of 15), and benign (2 of 14) tumors contained iNOS-positive macrophages. Notable was that COX-2- and iNOS-positive macrophages were predominantly located in the tumor stroma, the regions between tumor and stroma, and in the lumina of the tumor when located in the tumor tissue. These data indicate that not only malignant but also borderline and benign ovarian tumors can exhibit increased levels of COX-2 and iNOS expression. In addition, a small proportion of the tumor-associated macrophages found in malignant, borderline, and benign tumors seems to be in an activated state, judged by their iNOS and COX-2 expression. This subpopulation of tumor-associated macrophages was invariably located in the tumor stroma or in the lumina of the tumor, specifically suggesting that macrophages outside the tumor can be tumor cytotoxic.
This article has been cited by other articles:
|
|
 |
|
  Y.-Q. Zhang, S. Resta, B. Jung, K. E. Barrett, and N. Sarvetnick Upregulation of activin signaling in experimental colitis Am J Physiol Gastrointest Liver Physiol, October 1, 2009; 297(4): G768 - G780. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Tiwari-Pandey and M. Ram Sairam Modulation of Ovarian Structure and Abdominal Obesity in Curcumin- and Flutamide-treated Aging FSH-R Haploinsufficient Mice Reproductive Sciences, June 1, 2009; 16(6): 539 - 550. [Abstract] [PDF]
|
|
|
|
 |
|
 T. Hagemann, S. K. Biswas, T. Lawrence, A. Sica, and C. E. Lewis Regulation of macrophage function in tumors: the multifaceted role of NF-{kappa}B Blood, April 2, 2009; 113(14): 3139 - 3146. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Guruvayoorappan Tumor Versus Tumor-Associated Macrophages: How Hot is the Link? Integr Cancer Ther, June 1, 2008; 7(2): 90 - 95. [Abstract] [PDF]
|
|
|
|
 |
|
 I. Sugihara, M. Yoshida, T. Shigenobu, H. Takagi, K. Maruyama, N. Takeuchi, M. Toda, M. Inoue, and H. Nakada Different Progression of Tumor Xenografts between Mucin-Producing and Mucin-Non-Producing Mammary Adenocarcinoma-Bearing Mice. Cancer Res., June 15, 2006; 66(12): 6175 - 6182. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. E. Lewis and J. W. Pollard Distinct Role of Macrophages in Different Tumor Microenvironments Cancer Res., January 15, 2006; 66(2): 605 - 612. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Daikoku, D. Wang, S. Tranguch, J. D. Morrow, S. Orsulic, R. N. DuBois, and S. K. Dey Cyclooxygenase-1 Is a Potential Target for Prevention and Treatment of Ovarian Epithelial Cancer Cancer Res., May 1, 2005; 65(9): 3735 - 3744. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Symowicz, B. P. Adley, M. M.M. Woo, N. Auersperg, L. G. Hudson, and M. S. Stack Cyclooxygenase-2 Functions as a Downstream Mediator of Lysophosphatidic Acid to Promote Aggressive Behavior in Ovarian Carcinoma Cells Cancer Res., March 15, 2005; 65(6): 2234 - 2242. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Sirois, K. Sayasith, K. A. Brown, A. E. Stock, N. Bouchard, and M. Dore Cyclooxygenase-2 and its role in ovulation: a 2004 account Hum. Reprod. Update, September 1, 2004; 10(5): 373 - 385. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. Spinella, L. Rosano, V. Di Castro, M. R. Nicotra, P. G. Natali, and A. Bagnato Inhibition of Cyclooxygenase-1 and -2 Expression by Targeting the Endothelin A Receptor in Human Ovarian Carcinoma Cells Clin. Cancer Res., July 15, 2004; 10(14): 4670 - 4679. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Davydova, L. P. Le, T. Gavrikova, M. Wang, V. Krasnykh, and M. Yamamoto Infectivity-Enhanced Cyclooxygenase-2-Based Conditionally Replicative Adenoviruses for Esophageal Adenocarcinoma Treatment Cancer Res., June 15, 2004; 64(12): 4319 - 4327. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T.-L. Erkinheimo, H. Lassus, P. Finne, B. P. van Rees, A. Leminen, O. Ylikorkala, C. Haglund, R. Butzow, and A. Ristimaki Elevated Cyclooxygenase-2 Expression Is Associated with Altered Expression of p53 and SMAD4, Amplification of HER-2/neu, and Poor Outcome in Serous Ovarian Carcinoma Clin. Cancer Res., January 15, 2004; 10(2): 538 - 545. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 O. Gallo, N. Schiavone, L. Papucci, I. Sardi, L. Magnelli, A. Franchi, E. Masini, and S. Capaccioli Down-Regulation of Nitric Oxide Synthase-2 and Cyclooxygenase-2 Pathways by p53 in Squamous Cell Carcinoma Am. J. Pathol., August 1, 2003; 163(2): 723 - 732. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Inaba, H. Sano, Y. Kawahito, T. Hla, K. Akita, M. Toda, I. Yamashina, M. Inoue, and H. Nakada Induction of cyclooxygenase-2 in monocyte/macrophage by mucins secreted from colon cancer cells PNAS, March 4, 2003; 100(5): 2736 - 2741. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. A. Gupta, L. V. Tejada, B. J. Tong, S. K. Das, J. D. Morrow, S. K. Dey, and R. N. DuBois Cyclooxygenase-1 is Overexpressed and Promotes Angiogenic Growth Factor Production in Ovarian Cancer Cancer Res., March 1, 2003; 63(5): 906 - 911. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. J. Sales, A. A. Katz, R. P. Millar, and H. N. Jabbour Seminal plasma activates cyclooxygenase-2 and prostaglandin E2 receptor expression and signalling in cervical adenocarcinoma cells Mol. Hum. Reprod., December 1, 2002; 8(12): 1065 - 1070. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. G. Banerjee, V. K. Gopalakrishnan, I. Bhattacharya, and J. K. Vishwanatha Deregulated Cyclooxygenase-2 Expression in Oral Premalignant Tissues Mol. Cancer Ther., December 1, 2002; 1(14): 1265 - 1271. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. L. Nasi and M. Castiglione Cyclooxygenase-2 (COX-2) a new prognostic and predictive factor for ovarian cancer? Are all the criteria fulfilled? Ann. Onc., August 1, 2002; 13(8): 1169 - 1171. [Full Text] [PDF]
|
|
|
|
|
|
C. Denkert, M. Kobel, S. Pest, I. Koch, S. Berger, M. Schwabe, A. Siegert, A. Reles, B. Klosterhalfen, and S. Hauptmann Expression of Cyclooxygenase 2 Is an Independent Prognostic Factor in Human Ovarian Carcinoma Am. J. Pathol., March 1, 2002; 160(3): 893 - 903. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |
